

Professor Carole Longson
Director, Centre for Health Technology Evaluation
By e-mail c/o Kate.Moore@nice.org.uk



13 September 2011

Dear Professor Longson

Re: Advanced/metastatic breast cancer - fulvestrant - ACD Consultation

The Royal College of Physicians (RCP) plays a leading role in the delivery of high quality patient care by setting standards of medical practice and promoting clinical excellence. We provide physicians in the United Kingdom and overseas with education, training and support throughout their careers. As an independent body representing over 25,000 Fellows and Members worldwide, we advise and work with government, the public, patients and other professions to improve health and healthcare.

I write on behalf of the NCRI/RCP/RCR/ACP/JCCO with regard to the above ACD consultation. We are grateful for the opportunity to respond and would like to make the following comments.

Has all of the relevant evidence been taken into account?

We believe that all the relevant evidence had been taken into account.

Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

The summaries of clinical and cost effectiveness are reasonable interpretations of the evidence.

Are the provisional recommendations sound and a suitable basis for guidance to the NHS?

The provisional recommendations are sound and a suitable basis for guidance to the NHS.

Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?

In the opinion of our experts there are no aspects of the recommendations that would be discriminatory.

Yours sincerely

